Lysosomal Therapeutics Lands $20,000,000 Series A Financing

  • Feed Type
  • Date
    2/3/2015
  • Company Name
    Lysosomal Therapeutics
  • Mailing Address
    19 Blackstone Street Cambridge, MA 02139 USA
  • Company Description
    LTI’s unique approach to discovering new drugs for neurodegenerative diseases is based on research performed in the lab of Dr. Dimitri Krainc, one of the company’s founders, at Massachusetts General Hospital (MGH), a founding member of Partners HealthCare and an affiliate of Harvard Medical School.
  • Website
    http://www.lysosomaltx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will fund ongoing compound optimization and preclinical development of a glucocerebrosidase (GCase) lysosomal enzyme activator candidate for the treatment of Parkinson’s disease. In addition, the funding will support a biomarker initiative, for which LTI has previously received grant funding from The Michael J. Fox Foundation for Parkinson’s Research.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy